Welcome to LookChem.com Sign In|Join Free

HENAN SUNLAKE ENTERPRISE CORPORATION

Free supplier Enterprise Certification

Free
supplier
9th
years

Search in the shop

  • Search in the shop
  • Search the station
Home>>Products>>341031-54-7 C22H27FN4O2.C4H6O5 Sunitinib Malate

Products Categories

Product Certification&
Enterprise Certification

More Detail

HENAN SUNLAKE ENTERPRISE CORPORATION

Country: China (Mainland)

Business Type:Trading Company

Ms.summer

Tel: +86-371- 86259723

Mr.William

Tel: 17734809689

Ms.lisa

Tel: 17734809689

Ms.Tina

Tel: 86-371-86259723

Ms.Ann

Tel: 17734809689

Ms.Helen

Tel: 17734809689

Mobile: 17734809689

Tel: +86-371- 86259723

Fax: +86-371- 86259723

Province/state: HENAN

City: ZHENGZHOU

Street: Mingmen International Center, NO.222 Dongming Road,Zhengzhou,Henan,China

MaxCard:


qq Contact Suppliers

341031-54-7 C22H27FN4O2.C4H6O5 Sunitinib Malate

CAS NO.341031-54-7

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,D/A,D/P,T/T,
Contact Supplier

Product Details

Keywords

  • SUNITINIB MALATE
  • hydroxybutanedioate
  • 2-hydroxybutanedioatesalt

Quick Details

  • ProName: 341031-54-7 C22H27FN4O2.C4H6O5 Sunit...
  • CasNo: 341031-54-7
  • Molecular Formula: C22H27FN4O2.C4H6O5
  • Appearance: Yellow Solid
  • Application: 341031-54-7 ...
  • DeliveryTime: 7-10 days after payment
  • PackAge: As required
  • Port: Shanghai/Tianjin/Qingdao
  • ProductionCapacity: 100-200 Kilogram/Month
  • Purity: 99%
  • Storage: Store at +4°C
  • Transportation: By air/sea/express
  • LimitNum: 1 Kilogram
  • Grade: Pharma Grade

Superiority

About Certificate

 

1.Certificate Of Analysis (COA)
2.Material Safety Data Sheet (MSDS)
3.Route of synthesis (ROS)
4.Method of Aanlysis(MOA)
5.Nuclear Magnetic Resonance(NMR)

 

About Service

 

1. Quality control, before shipment, free sample for test.
2. Prompt shipment with professional documents
3. Packing as your request, with photo before shipment
4. Mixed containers with different mixed items in one container

 

About Company

 
HenNan sunlake enterprise corporation is located in Henan Province , The central plain of China , Which enjoys favorable geogeaphical position and convenient transportion, The com[any was established in june. 1998 , until now having more than 18 years experience in manufacturing & exporting chemical raw material .
     Sunlake is a professional manufacturer engaged in producing and selling chemicals,including Organic & inorganic chemicals , pigments & Dyestuffs ,  Water treatment chemicals , Food & FEED additives and others . these products have been being well exported to europe , southeast Asia , the Middle East ,  Africa , South America and some other countries and areas.
    We sincerely welcome foreign friends to visit our plant for cooperation. With the idea of "quality first,credit priority, Excellent service", We are highly acknowledged by customers for good quality and competitive price. More importantly , the company has a strong R & D team, who are professional engineers and scholars with Ph. D. .So we are confident to serve you  better with our high - quality products and professional team.
    We are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional wupplier in international market.
     We  welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate with you for a brilliant future!

Details

Product Name: Sunitinib Malate
Synonyms: SUNITINIB MALATE;N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate;N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide(2S)-2-hydroxybutanedioatesalt;Sunitinib Malate(Sutent);Butanedioic acid, 2-hydroxy-, (2S)-, coMpd. with N-[2-(diethylaMino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)Methyl]-2,4-diMethyl-1H-pyrrole-3-carboxaMide (1:1);N-(2-(DiethylaMino)ethyl)-5-((Z)-(5-fluoro-1,2-dih;Butanedioic acid, 2-hydroxy-, (2S)-, coMpd. with N-[2-(diethylaMino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)Methyl]-2,4-diMethyl-1H-pyrrole-3-carboxaMide;(Z)-N-(2-(diethylaMino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)Methyl)-2,4-diMethyl-1H-pyrrole-3-carboxaMide (S)-2-hydroxysuccinate
CAS: 341031-54-7
MF: C22H27FN4O2.C4H6O5
MW: 532.566
EINECS:  
Product Categories: APIs;Heterocycles;Intermediates & Fine Chemicals;Pfizer compounds;Pharmaceuticals;Tyrosine Kinase Inhibitors;SU-11248;Inhibitors
Mol File: 341031-54-7.mol
Sunitinib Malate Structure
 
Sunitinib Malate Chemical Properties
mp  189-191°C
storage temp.  Store at +4°C
CAS DataBase Reference 341031-54-7(CAS DataBase Reference)
 
Safety Information
Hazard Codes  T
Risk Statements  61-2-48/25
Safety Statements  53-22-36/37
MSDS Information
 
 
Sunitinib Malate Usage And Synthesis
Anticancer drug Sunitinib malate is a kind of novel oral multi-targeted anticancer drugs and belongs to multi-targeted tyrosine kinase inhibitor with its trade name being “suntent”. It was successfully developed by Pfizer Company and has dual anti-tumor effect. Moreover, it is the only therapeutic drug which can go beyond the 2-year survival period of advanced kidney cancer and plays a central role in the field of carcinoma and gastrointestinal stromal tumor therapeutic areas. It entered into market in February 2006 in the United States. This drug was the first anti-cancer drug which was approved by the US FDA and can simultaneously treat two diseases.
Sunitinib exerts its therapeutic role through preventing the tumor cells from getting the blood and nutrients needed for growth. Clinical trials have showed that the drug can delay the growth rate of gastrointestinal stromal tumors, and can shrink the size of renal cell tumors. Sunitinib malate is the first novel targeted drug being capable of selectively targets drugs for a variety of new tyrosine kinase receptors. It combine two kinds of anti-tumor mechanisms including both stopping the formation of anti-angiogenic which is responsible for supplying blood to tumor and direct attack of tumor cells. It represents the advent of a new round of targeted therapies, being able to attack the tumor directly without the toxicity of the conventional chemotherapy.
The indications of Sunitinib malate are as follows:
1, Patients who failed in the treatment with matinib mesylate or of intolerant gastrointestinal stromal tumors (GIST).
2, inoperable advanced renal cell carcinoma (RCC).
3, advanced pancreatic endocrine tumors.
The above information is edited by the Chemicalbook of Dai Xiongfeng.
Application Anti-cancer drugs
Chemical Properties Yellow Solid
Usage Sunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.
Usage Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit
Usage A multi-kinase inhibitor targeting several receptor tyrosine kinases (RTK). Antineoplastic.
Biological Activity Potent, ATP-competitive VEGFR, PDGFR β and KIT inhibitor (K i values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFR β and KIT respectively). Also inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models.
 
Sunitinib Malate Preparation Products And Raw materials

 

lookchemhot productCASNew CAS Cas Database Article Data Chemical Catalog
Hot Product